PTSD

Military Makeover with Montel® Honors the Resilience and Service of Jared Bowman and Family in Upcoming Season

Retrieved on: 
Thursday, January 4, 2024

STATESVILLE, N.C., Jan. 4, 2024 /PRNewswire/ -- Military Makeover with Montel® along with Official Non-Profit Partner, Purple Heart Homes, proudly announces the next veteran recipient of a home makeover, Jared Bowman and his deserving family. Jared Bowman, a 35-year-old native of Raleigh, North Carolina, embodies resilience, dedication, and commitment to his country and loved ones.

Key Points: 
  • Jared Bowman, a 35-year-old native of Raleigh, North Carolina, embodies resilience, dedication, and commitment to his country and loved ones.
  • "Each season of Military Makeover is an opportunity to honor our heroes, weaving stories of resilience and transformation," says Scott Moss, President & EVP of Programming for Military Makeover and BrandStar Entertainment.
  • "Jared and his family could not be more deserving, and I am excited to see this renovation complete.
  • Military Makeover with Montel is honored to feature the Bowman Family as the recipients of this season's home makeover.

PTSD: The Brain Basis of Susceptibility - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Wednesday, January 3, 2024

New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at 2:00 pm ET.

Key Points: 
  • New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at 2:00 pm ET.
  • The presenter will be Nathaniel G. Harnett, Ph.D., Director of the NATE Lab at McLean Hospital and Assistant Professor in Psychiatry at Harvard Medical School.
  • The webinar will be hosted by Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds.
  • This webinar will highlight emerging research supported by BBRF that has begun to identify the brain circuits that contribute to PTSD susceptibility and may be used to predict future PTSD symptoms.

A brief history of drug-fuelled combatants

Retrieved on: 
Tuesday, January 2, 2024

I don’t know whether he thought that it might reduce pain or improve performance, but the idea of taking drugs before “going into battle” goes back to the beginning of recorded history.

Key Points: 
  • I don’t know whether he thought that it might reduce pain or improve performance, but the idea of taking drugs before “going into battle” goes back to the beginning of recorded history.
  • Indeed, we find frequent mentions of mead drinking by the warriors in Edinburgh in the seventh-century epic poem The Goddodin.
  • These ancient warriors probably used alcohol to reduce anxiety and blunt the horrors they would face on the battlefield.
  • Pervitin (methamphetamine) was given almost freely to all arms of the German war machine.
  • The frontline Nazis called them Panzerschokolade (tank chocolate), due to the feelings of incredible strength and invincibility that the pills gave them.

Behavioural effects


The types of drugs taken by warriors can be lumped into three broad categories: depressants, hallucinogens and stimulants. Alcohol is a depressant that calms the nerves by reducing brain activity. Psychedelic mushrooms such as Amanita muscaria contain a variety of psychoactive substances. Hyoscyamus niger also has a variety of active compounds that cause hallucinations and, importantly, aggressive and combative behaviour.

  • The word “groggy” meaning dazed and unsteady came from British navy sailors exhibiting this behaviour after their daily ration of rum and water (grog).
  • The stimulants, but especially methamphetamine, would also lead to significant weight loss even after only a few days of use.
  • Long-term use, as we saw with the Nazis, would probably lead to emaciated soldiers.

Smart drugs

  • We have seen that soldiers take drugs before battles to calm nerves, deal with the horrors, reduce pain, tolerate lack of food and sleep and improve alertness.
  • The stimulants include drugs such as amphetamine salt mixtures, methylphenidate and modafinil, while nootropics include piracetam, caffeine, cobalamin (vitamin B12), guarana, pyridoxine (vitamin B6) and vinpocetine.
  • The integration of humans, technology and machines is thought to be the future of warfare and drugs that facilitate this are undoubtedly being researched by the military.

Post-traumatic stress disorder

  • There is a long history of soldiers taking alcohol and other drugs to deal with the horrors of what they have seen, or the disappointment of life after leaving the army.
  • These veterans are taking MDMA and psilocybin on doctors’ orders as part of their treatment for PTSD.
  • Ketamine is useful for treating depression and LSD is also being tested for various psychiatric disorders.


Colin Davidson has previously received funding from the US National Institute on Drug Abuse (NIDA). He is a consultant with the Defence Science and Technology Laboratory (UK).

MAPS PBC Announces New American Medical Association CPT III Codes for Psychedelic-Assisted Therapies Take Effect

Retrieved on: 
Tuesday, January 2, 2024

SAN JOSE, Calif., Jan. 2, 2024 /PRNewswire/ -- MAPS Public Benefit Corporation ("MAPS PBC"), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced that the American Medical Association ("AMA") current procedural terminology ("CPT") III codes for psychedelic-assisted therapies, first announced in July 2023, are now in effect. The new CPT codes will provide physicians and other qualified healthcare providers a means to seek coverage and reimbursement for delivering psychedelic-assisted therapy if approved by the U.S. Food and Drug Administration ("FDA").

Key Points: 
  • SAN JOSE, Calif., Jan. 2, 2024 /PRNewswire/ -- MAPS Public Benefit Corporation ("MAPS PBC"), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced that the American Medical Association ("AMA") current procedural terminology ("CPT") III codes for psychedelic-assisted therapies, first announced in July 2023, are now in effect.
  • MAPS PBC and COMPASS Pathways collaborated to work with the AMA to create these new CPT III codes.
  • On March 3, 2023, the AMA published the Summary of Panel Actions which included the acceptance of the new CPT III codes.
  • With Breakthrough Therapy designation given to MDMA in 2017, MAPS PBC has requested the FDA grant Priority Review of the NDA.

Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications

Retrieved on: 
Tuesday, January 2, 2024

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein.
  • CKD Bio is a subsidiary of Chong Kun Dang group based in Seoul, South Korea.
  • Healis Therapeutics intends to develop CKDB-501 for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).
  • “Our collaboration with CKD Bio on this new agreement could one day impact over 42 million Americans” said Sebastian De Beurs, Co-Founder of Healis.

PharmAla Files Audited Financials for Year Ending August 31, 2023

Retrieved on: 
Friday, December 29, 2023

- PharmAla’s LaNeo™ GMP Drug Product was submitted and allowed for clinical trial use by the USFDA; PharmAla is currently supporting over 10 clinical trials globally with LaNeo.

Key Points: 
  • - PharmAla’s LaNeo™ GMP Drug Product was submitted and allowed for clinical trial use by the USFDA; PharmAla is currently supporting over 10 clinical trials globally with LaNeo.
  • “This has been an exciting year for PharmAla, and for MDMA more broadly,” said Nick Kadysh, CEO, PharmAla Biotech.
  • We are excited to continue to build off of the milestones we achieved at PharmAla in 2023.
  • The recent filing of the MAPS New Drug Application for MDMA-Assisted Therapy for PTSD provides a favourable industry tailwind.

PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens

Retrieved on: 
Wednesday, November 29, 2023

This webinar will explore the intersection of neuroscience and psychedelics, highlighting their potential therapeutic benefits for mental health conditions such as depression, anxiety, PTSD, and addiction.

Key Points: 
  • This webinar will explore the intersection of neuroscience and psychedelics, highlighting their potential therapeutic benefits for mental health conditions such as depression, anxiety, PTSD, and addiction.
  • Dr. Reichelt will delve into the neurobiology of psychedelics, emphasizing their role in promoting neuroplasticity, which allows for the rewiring of the brain.
  • Ongoing clinical research will also be discussed, including the use of these substances in controlled settings to address trauma, reduce symptoms, and tackle substance dependence.
  • Finally, Dr. Reichelt will explore next-generation psychedelics without hallucinatory effects and the potential of psychedelics as innovative therapeutic tools in psychiatry and neurology.

CLEAN AI, Creator of Text-to-Video 360-Degree Experiences, to Launch Dreamscapes Immersive App

Retrieved on: 
Tuesday, November 14, 2023

The innovative technology will allow users to relax in peaceful settings that include tropical beaches, jungles, mountains, city scapes, and outer space.

Key Points: 
  • The innovative technology will allow users to relax in peaceful settings that include tropical beaches, jungles, mountains, city scapes, and outer space.
  • "Our goal is to use VR and immersive technology to support patients with PTSD and ADHD," MacDonald explains.
  • MacDonald and her team are also preparing to launch CLEAN AI's latest achievement: its library of 8D sounds, with categories including Rest & Relaxation, Focus, and Work/Study.
  • CLEAN AI is providing the tools to empower them so that they can feel more at peace."

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Retrieved on: 
Thursday, December 21, 2023

MELBOURNE, Australia and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that it has received ethics board endorsement for psychedelic assisted therapy at its first clinic based in Melbourne, Australia, a city of approximately 5.2M people.

Key Points: 
  • Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD.
  • Clarion Clinics is the only dedicated psychedelic-assisted therapy clinic in Australia, with intentions to open more clinics across the country and internationally as legislation permits.
  • Clarion Clinics team includes pre-eminent psychedelic researchers, psychologists and psychiatrists whose expertise can not easily be replicated in Australia.
  • The Melbourne Clarion Clinic will be the first dedicated Psychedelic-assisted therapy clinic in Australia.

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Retrieved on: 
Thursday, December 21, 2023

Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.

Key Points: 
  • Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.
  • The agreement stems from a collaboration between Pluri and Bar-Ilan University researchers that presented compelling findings.
  • The studies evaluated PLX-PAD cells’ efficacy in treating cocaine addiction in animal models.
  • Across North America and Europe, demand for treatment has steadily increased over the last decade, according to the U.N. Office on Drugs and Crime.